Summary by Moomoo AI
NeuroSense Therapeutics Ltd., a company specializing in neurological treatments, has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form F-1, filed on May 10, 2024, will not undergo review. The SEC's communication, dated May 14, 2024, was addressed to Alon Ben-Noon, CEO of NeuroSense Therapeutics, and was sent from the Division of Corporation Finance, Office of Life Sciences. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Additionally, the SEC reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC provided contact information for Tim Buchmiller.
